Immunotherapy with or without targeted therapy for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy (carboplatin/paclitaxel), followed by more immunotherapy, with or without an additional targeted drug (apatinib), for advanced or recurrent endometrial cancer. It aims to see if adding the targeted drug improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (stage III or IV) or first recurrent endometrial cancer that is not likely to be cured by surgery or radiation.
- Your cancer type is not sarcoma.
- You have not had more than one line of prior systemic treatment (including chemo or hormone therapy), or you relapsed at least 6 months after completing treatment.
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) or certain targeted anti-angiogenic drugs before.
- You are generally in good health (ECOG score 0-2) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial studies a new drug called cadonilimab combined with chemotherapy for women with endometrial cancer that has come back or spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Hear when a new Recurrent/Metastatic Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.